$1.83
-0.0407-2.18%
Last update: Nov 9, 4:00 PM
Xenetic Biosciences Inc
XBIONASDAQ
Xenetic Biosciences fell 32.2% from $2.65 to $1.80, behind the S&P 500's +10.5%. Its worst day was Sep 16 (−48.7%), and its low came Oct 23 at $1.70.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.33 beat the $-0.51 estimate on $1.0M revenue (est. $525,000.00).
−2.7% · S&P 500 −1.7%
Xenetic Biosciences shares rose 14.5%, while the S&P 500 rose 0.5%.
Story events cover the past 12 months · Times ET
+14.5% · S&P 500 +0.5%
EPS of $-0.22 beat the $-0.52 estimate on $766,296.00 revenue (est. $525,000.00).
+9.7% · S&P 500 −0.6%
EPS of $-0.20 was reported on $806,923.00 revenue.
+8.2% · S&P 500 +0.6%
EPS of $-0.41 was reported on $660,601.00 revenue.
+11.2% · S&P 500 +0.6%
Xenetic Biosciences closed at its highest level of the year, 76.2% above where the year started.
+0.9% · S&P 500 −0.4%
Xenetic Biosciences shares fell 48.7%, while the S&P 500 fell 0.4%.
−48.7%, the year's worst day, on 2M shares, the year's heaviest volume · S&P 500 −0.4%
Xenetic Biosciences closed at its lowest level of the year, 35.8% below where the year started.
−11.9% · S&P 500 −0.5%
Where it ended: a close of $1.80 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026.
Nothing in the past 12 months.
All XBIO analyst actionsNothing in the past 12 months.
All XBIO dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for XBIO and SPY from Benzinga historical bars. Not investment advice.
